A citation-based method for searching scientific literature

Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda. Respirol Case Rep 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan,[...]. PLoS One 2013
84
100


Functional characterization of NTRK1 mutations identified in melanoma.
Claudia Miranda, Mara Mazzoni, Marialuisa Sensi, Marco A Pierotti, Angela Greco. Genes Chromosomes Cancer 2014
14
100

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
100

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Mariangela Russo, Sandra Misale, Ge Wei, Giulia Siravegna, Giovanni Crisafulli, Luca Lazzari, Giorgio Corti, Giuseppe Rospo, Luca Novara, Benedetta Mussolin,[...]. Cancer Discov 2016
195
100

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
193
100

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
159
100


TrkA overexpression enhances growth and metastasis of breast cancer cells.
C Lagadec, S Meignan, E Adriaenssens, B Foveau, E Vanhecke, R Romon, R-A Toillon, B Oxombre, H Hondermarck, X Le Bourhis. Oncogene 2009
141
100

Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies.
Fabien Vincent, Paula M Loria, Andrea D Weston, Claire M Steppan, Regis Doyonnas, Yue-Ming Wang, Kristin L Rockwell, Marie-Claire Peakman. Cell Chem Biol 2020
15
100

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
132
100

Opportunities and challenges in phenotypic drug discovery: an industry perspective.
John G Moffat, Fabien Vincent, Jonathan A Lee, Jörg Eder, Marco Prunotto. Nat Rev Drug Discov 2017
341
100

The trk proto-oncogene encodes a receptor for nerve growth factor.
R Klein, S Q Jing, V Nanduri, E O'Rourke, M Barbacid. Cell 1991
100

Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia.
G W Reuther, Q T Lambert, M A Caligiuri, C J Der. Mol Cell Biol 2000
82
100

Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells.
Angelika Eggert, Michael A Grotzer, Naohiko Ikegaki, Xing-ge Liu, Audrey E Evans, Garrett M Brodeur. Cancer Res 2002
78
100

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.
Anna Saborowski, Michael Saborowski, Monika A Davare, Brian J Druker, David S Klimstra, Scott W Lowe. Proc Natl Acad Sci U S A 2013
56
100

The anaplastic lymphoma kinase in the pathogenesis of cancer.
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami. Nat Rev Cancer 2008
588
100

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Christian Rolfo, Rossana Ruiz, Elisa Giovannetti, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Marco Giallombardo, Marc Peeters, Luis Raez. Expert Opin Investig Drugs 2015
75
100

Phenotypic screening: the future of antibody discovery.
Andrea L Gonzalez-Munoz, Ralph R Minter, Steven J Rust. Drug Discov Today 2016
13
100

Role and relevance of TrkB mutations and expression in non-small cell lung cancer.
Taishi Harada, Yasushi Yatabe, Masafumi Takeshita, Takaomi Koga, Tokujiro Yano, Yisong Wang, Giuseppe Giaccone. Clin Cancer Res 2011
43
100

Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer.
Marta Fonseca, Daniel H Chen, John Malcolm Walker, Arjun K Ghosh. BMJ Case Rep 2021
1
100


Inhibiting TRK Proteins in Clinical Cancer Therapy.
Allison M Lange, Hui-Wen Lo. Cancers (Basel) 2018
89
100

Cell and small animal models for phenotypic drug discovery.
Mihaly Szabo, Sara Svensson Akusjärvi, Ankur Saxena, Jianping Liu, Gayathri Chandrasekar, Satish S Kitambi. Drug Des Devel Ther 2017
20
100

ROS receptor tyrosine kinase: a new potential target for anticancer drugs.
Ibrahim Mustafa El-Deeb, Kyung Ho Yoo, So Ha Lee. Med Res Rev 2011
43
100

Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.
Seong-Wook Seo, Dong-Gyun Han, Eugene Choi, Taeuk Park, Jong Hyuk Byun, Hyun-Jong Cho, Il Hyo Jung, In-Soo Yoon. Biomed Pharmacother 2022
2
100

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Dana S Neel, David V Allegakoen, Victor Olivas, Manasi K Mayekar, Golzar Hemmati, Nilanjana Chatterjee, Collin M Blakely, Caroline E McCoach, Julia K Rotow, Anh Le,[...]. Cancer Res 2019
33
100

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
N Rajan, R Elliott, O Clewes, A Mackay, J S Reis-Filho, J Burn, J Langtry, M Sieber-Blum, C J Lord, A Ashworth. Oncogene 2011
40
100

Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype.
V Girish, N Sachdeva, R W Minz, B Radotra, S N Mathuria, S K Arora. Indian J Pathol Microbiol 2005
5
100

Virtual screening strategies in drug discovery.
Campbell McInnes. Curr Opin Chem Biol 2007
229
100

Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
Neil Parrott, Cordula Stillhart, Marc Lindenberg, Bjoern Wagner, Karey Kowalski, Elena Guerini, Nassim Djebli, Georgina Meneses-Lorente. AAPS J 2020
10
100

In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening.
Xiao Hua Ma, Zhe Shi, Chunyan Tan, Yuyang Jiang, Mei Lin Go, Boon Chuan Low, Yu Zong Chen. Pharm Res 2010
101
100


What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, D M Hyman, J Hechtman, G Wei,[...]. Ann Oncol 2016
188
100

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
24
100

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima,[...]. Nat Commun 2019
61
100

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Holly L Pacenta, Margaret E Macy. Drug Des Devel Ther 2018
18
100


Entrectinib: First Global Approval.
Zaina T Al-Salama, Susan J Keam. Drugs 2019
50
100

Next-generation phenotypic screening.
Scott J Warchal, Asier Unciti-Broceta, Neil O Carragher. Future Med Chem 2016
32
100

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.
S W Morris, M N Kirstein, M B Valentine, K G Dittmer, D N Shapiro, D L Saltman, A T Look. Science 1994
100

Expression and localization of c-ros oncogene along the human excurrent duct.
Christine Légaré, Robert Sullivan. Mol Hum Reprod 2004
21
100

The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer.
Jaime Acquaviva, Ricky Wong, Al Charest. Biochim Biophys Acta 2009
129
100

Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Clare Keddy, Tanaya Neff, Jianya Huan, Joshua P Nickerson, Catherine Z Beach, Yassmine Akkari, Jianling Ji, Stephen Moore, Kellie J Nazemi, Christopher L Corless,[...]. Cold Spring Harb Mol Case Stud 2021
3
100

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
Christine M Lovly, Johannes M Heuckmann, Elisa de Stanchina, Heidi Chen, Roman K Thomas, Chris Liang, William Pao. Cancer Res 2011
168
100


From magic bullets to designed multiple ligands.
Richard Morphy, Corinne Kay, Zoran Rankovic. Drug Discov Today 2004
511
100

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
449
100

Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
Kensuke Suzuki, Hiroshi Harada, Masayuki Takeda, Chisato Ohe, Yoshiko Uemura, Akihiko Kawahara, Shunsuke Sawada, Akira Kanda, Bhaswati Sengupta, Hiroshi Iwai. BMC Med Genomics 2022
1
100

Pharmacophore-based virtual screening.
Hongma Sun. Curr Med Chem 2008
100
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.